The Asia-Pacific gastric cancer market is forecast to grow at a compound
annual growth rate of 11.4% from $1.3 billion in 2015 to $2.7 billion in
2022.

The current marketed products landscape comprises a wide range of
treatment options, including HER2-targeted therapy, angiogenesis
inhibitors and new chemotherapies. Nevertheless, significant unmet need
remains for products that can treat HER2-negative gastric cancer
patients. However, the gastric cancer market is undergoing a gradual
change from a focus on generic chemotherapy regimens to a complex
treatment landscape based on targeted therapies.

In the current market, patients with HER2-positive gastric cancer can be
treated with targeted therapies, such as Herceptin, while HER2-negative
patients still receive chemotherapy regimens as the first-line
treatment. The market will be driven by recently launched products and
upcoming targeted therapies during the forecast period. The main
restraints will be the low penetration of new targeted therapies, owing
to their high price, and constrained healthcare budgets.

Key Topics Covered:

1 Tables & Figures

2 Introduction

2.1 Disease Introduction

2.2 Epidemiology

2.3 Symptoms

2.4 Etiology

2.5 Pathophysiology

2.6 Diagnosis

2.7 Classification and Disease Staging

2.8 Prognosis

2.9 Treatment Guidelines and Options

3 Marketed Products

3.1 Overview

3.2 HER2-Targeted Therapy

3.3 Angiogenesis Inhibitors

3.4 Newer Chemotherapies

3.5 Comparative Efficacy and Safety of Marketed Products

4 Pipeline Analysis

4.1 Overview

4.2 Pipeline by Stage of Development, Molecule Type, Route of
Administration and Program Type

4.3 Pipeline by Molecular Target

4.4 Promising Pipeline Candidates

4.5 Comparative Efficacy and Safety of Pipeline Products

4.6 Product Competitive Framework

5 Clinical Trial Analysis

5.1 Failure Rate

5.2 Clinical Trial Size

5.3 Clinical Trial Duration

5.4 Summary of Clinical Trial Metrics

6 Multi-Scenario Forecast

7 Market Dynamics

7.1 Drivers

7.1.1 Increasing Prevalence and Treatment Rate Across All Lines of
Therapy in the Metastatic Setting

7.1.2 Promising Drug Pipeline Focused on Targeted Therapies

7.1.3 Launch of Premium-Priced Drugs for the Metastatic Setting

7.1.4 Improved Treatment Options that Extend Duration of Therapy

7.1.5 Increasing Screening Programs and Government Reforms

7.2 Barriers

7.2.1 Lack of Development of Pipeline Agents as Pre-operative and
Postoperative Treatments for Resectable Gastric Cancer

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.